To investigate tumour progression mechanism in transgenic mouse skin carcinogenesis, inducible PTEN ablation (D5PTEN flx ) was targeted to the epidermis of mice expressing activated ras Ha /fos oncogenes (HK1.ras and HK1.fos). RU486-treated HK1.ras/fos-D5PTEN flx epidermis exhibited significant keratinocyte proliferation resulting in hyperplasia and proliferating cysts. While HK1.ras/ fos-D5PTEN flx papillomatogenesis was accelerated, malignant conversion was delayed and tumours exhibited well-differentiated squamous cell carcinoma (wdSCC) histotypes, suggesting inhibition of early-stage malignant progression. Immediate elevated p53/p21 expression was observed in HK1.ras/fos-D5PTEN flx hyperplasia, cysts and papillomas, and while malignant conversion required p53 loss, elevated p21 expression persisted in most wdSCCs to limit further progression, unless p21 was also lost and wdSCC progressed to more aggressive carcinomas. In contrast, TPA-promoted (that is, c-fos-activated) bi-genic HK1.ras-D5PTEN flx cohorts lost p53/p21 expression during early papillomatogenesis and rapidly produced poorly differentiated carcinomas (pdSCCs) with high BrdU-labelling and elevated cyclin D1/E2 expression levels, indicative of a progression mechanism driven by failures in cell-cycle control. Intriguingly, HK1.ras/fos-D5PTEN flx wdSCCs did not exhibit similar failures, as western and immunofluorescence analysis found downregulated cyclin E2 whenever p21 persisted; further, while westerns detected elevated cyclin D1, immunofluorescence identified reduced expression in proliferative basal layer nuclei and a redistributed expression profile throughout p21-positive wdSCC keratinocytes. These data demonstrate that rapid early epidermal responses to ras Ha /fos/DPTEN co-operation involve induction of p53/p21 to alter differentiation and divert excessive proliferation into cyst formation. Further, despite three potent oncogenic insults p53 loss was required for malignant conversion, and following p53 loss persistent, p53-independent p21 expression possessed the potency to limit early-stage malignant progression via cyclin D1/E2 inhibition.
INTRODUCTION
Carcinogenesis is driven by a complex combination of the genetic mutation milieu, their synergism or redundancy and whether the resultant cellular context created by linear/temporal acquisition of each mutation [1] [2] [3] activates sentinel systems within the cell/microenvironment that have evolved to resist tumour progression. [4] [5] [6] In clinical terms, conversion of benign tumours to malignancy is one of the most significant genetic/epigenetic events. However, it is unclear exactly when or whether a specific benign tumour will develop malignant potential 3 due to the many and varied progression/inhibition mechanisms 1,2 that collectively contribute to the heterogeneity that hinders therapeutic approaches. 7 Two major signalling pathways driving carcinogenesis involve activation of ras/MAPK signalling to fos/AP1 and disruption/ deregulation of the PTEN/PI3K/AKT pathway; [8] [9] [10] further, while p53 and p21 epitomize tumour suppressor gene functions, 11, 12 given their myriad roles in regulation of countless interacting pathways, exactly how they suppress stage-specific carcinogenesis remains elusive. In classic murine skin carcinogenesis, ras
Ha mutations are early initiating events, 13 while fos activation associates with papillomatogenesis, 14 being a major effector of TPA promotion. 15 Roles for p53 dysfunction are well established, particularly in malignant conversion, 16 yet are less clear for p21, which appears indifferent to papillomatogenesis in some models 17 but not others; 18, 19 further, its actions in epidermal differentiation independent of p53-associated cell cycle checkpoints 20 may help inhibit tumour progression. 21, 22 In human tumours, PTEN is mutated at high frequency, thus compromising the negative regulation of AKT activity 10 and disrupting direct interactions with p53, 4, 6 which also induce p21 expression. 21 PTEN heterozygosity underlies Cowden Disease, a cancer predisposition syndrome associated with cutaneous hyperkeratosis, suggesting major roles in epidermal differentiation 23 alongside activities essential for normal development. 10 Chemical carcinogenesis studies employing mutant PTEN mice associate downstream AKT activation with malignancy, either co-operating with DMBA-mutated ras Ha or not, [24] [25] [26] while PTEN loss cooperates with fos activation to elicit atypical keratinocyte 1 differentiation and keratoacanthomas. 27, 28 These transgenic studies highlight that the tumour outcomes of malignancy and progression depend upon the context created by synergistic mutations when pitted against inhibitory cellular/tissue responses. [3] [4] [5] [6] [7] [24] [25] [26] [27] Given that the epidermis is continually exposed to environmental carcinogens, multi-stage transgenic mouse skin carcinogenesis might be a useful model to investigate the potential of such sentinel systems and explore the nuances underlying the mechanisms that drive/inhibit tumour progression.
To this end, the consequences of inducible PTEN ablation (D5PTEN) in co-operation with ras Ha /fos oncogene activation (HK1.ras, HK1.fos) was assessed, 26, 27 and while HK1.ras/fos-D5PTEN flx synergism now achieved malignancy, malignant conversion was delayed due to rapid, immediate p53/p21 expression in preneoplastic phenotypes, which diverted excess keratinocyte proliferation into formation of novel cysts; moreover, following p53 loss, persistent p21 expression possessed the potency to limit early-stage malignant progression to wdSCC via altered cyclin D1/E2 expression.
RESULTS

HK1
.ras/fos-D5PTEN flx co-operation elicits epidermal hyperplasia, proliferating cysts and papilloma progression to wdSCC To investigate co-operation in multistage carcinogenesis, inducible PTEN ablation was assessed in transgenic mouse skin also expressing activated ras
Ha and fos oncogenes exclusively in transit amplifying, basal layer keratinocytes from a modified human keratin 1 promoter (HK1.ras; HK1.fos).
14,26,27 Six-week-old adult mouse skin was treated with RU486 to permanently ablate PTEN exon 5 in epidermal keratinocytes, follicles and stem cells by virtue of an inducible, keratin K14-driven cre recombinase (K14.creP). 29 As shown in Figure 1 (see also Supplementary Figure  S1 ), B6-7 weeks later, RU486-induced PTEN loss in (K14.crePexpressing) HK1.ras/fos-D5PTEN flx mice (n ¼ 16) produced overt, raised nodules underlying a relatively hairless skin (Figure 1a) , a novel phenotype absent in (K14.creP-expressing) bi-genic HK1.ras-D5PTEN flx , HK1.fos-D5PTEN flx and HK1.ras/fos controls. 14, 26, 27 These nodules derived from epidermal cysts (Figure 1b) , which had appeared in sizable numbers 4-5 weeks post RU486 treatment and gave an epidermal histology reminiscent of oral papilloamatosis/ scrotal tongue found in Cowden Disease. 23 Larger cysts separated from the epidermis proper, changing from typically thin-walled structures (Figure 1b) into discrete spherical lesions with a stratified epidermal histopathology that continued to proliferate but did not become cancerous (Figure 1c) .
A more subtle HK1.ras/fos-D5PTEN flx histopathology appeared in the architecture of papilloma basal layers (Figures 1d-f) , where keratinocyte differentiation became ragged, disordered and supra-basal layers possessed oedematous intercellular gaps giving a loose, spongiosis-like histotype (Figures 1d and e) , which suggests failures in the cell-cell adhesion that underpins epidermal integrity and aids early progression to malignancy. This histotype was preceded by strands of elongated basal layer keratinocytes/nuclei (Figure 1f ) in hyperplasia that may derive from the necessity to accommodate excessive keratinocyte proliferation. These tri-genic histotypes contrasted to bi-genic controls, as HK1.fos-D5PTEN flx (Figure 1g ) epidermis exhibits a histopathology dominated by atypical, accelerated differentiation, whereas hyperplastic bi-genic HK1.ras/fos (Figure 1h developed large, well-vascularized tumours that necessitated early biopsy (6 weeks). Non-promoted (RU486-treated) HK1.ras-D5PTEN flx mice exhibited stable papillomas that lacked conversion (not shown 26 ), whie bi-genic HK1.fos-D5PTEN flx siblings gave a separate KA aetiology (Figure 2d 27 ). Early tri-genic tumours (12-14 weeks; n ¼ 12) comprised a mix of papilloma, carcinoma in situ and wdSCC histotypes (Figure 2e) , with the disorganized papilloma basal layers (Figures 2g-i) indicative of malignant conversion. Later HK1.ras/fos-D5PTEN flx biopsies (18-20 weeks, n ¼ 28) comprised a uniform wdSCC histotype with increasing numbers of more aggressive SSC 'nests' (Figure 2h ) that remained predominantly wdSCC vs SCC by 24/26 weeks, whereas TPA-promoted, bi-genic HK1.ras-D5PTEN flx mice exhibited aggressive, pdSCC histotypes by 4-6 weeks (Figures 2f and j) . Nonpromoted bi-genic HK1.ras-D5PTEN flx controls exhibited stable papillomas, 26 whereas HK1.fos-D5PTEN flx KAs (Figure 2k ) displayed an atypical, accelerated keratinocyte differentiation. 27 Differentiation marker expression confirms limited malignant progression and an interfollicular origin to cyst aetiology Keratinocyte differentiation was analysed via expression of keratin K1, an early marker of keratinocyte differentiation, together with late-stage differentiation markers loricrin and filaggrin ( 
27
Analysis of late-stage differentiation markers loricrin and filaggrin in HK1.ras/fos-D5PTEN flx hyperplasia, cyst and papillomas showed that elevated loricrin expression was confined to an expanded granular compartment ( Figure 3 : loricrin panel; 1a and b) and retained throughout papillomatogenesis ( Figure 3 : loricrin panel; 1c) in a similar fashion to bi-genic cohorts, for example, HK1.ras-D5PTEN flx ( Figure 3 : loricrin panel; 1d), suggesting that tri-genic keratinocyte differentiation remained normalized to some extent. Loricrin expression also persisted into early wdSCCs consistent with an inhibited progression, which may derive from epidermal responses to fos/D5Pten synergism as loricrin expression was a prominent marker of the confused, accelerated differentiation that drove HK1.fos-D5PTEN flx KA aetiology ( Figure 3 : loricrin panel; 1e). 27 However, filaggrin expression was an early casualty of excessive keratinocyte proliferation ( Figure 3 : filaggrin panel; 1a), although low-level filaggrin expression rallied in larger cysts and papillomas ( Figure 3 : filaggrin panel; 1b and c) but not to levels observed in bi-genic HK1.fos-D5PTEN flx KA aetiology, where filaggrin expression also indicated accelerated, atypical differentiation ( Figure 3 : filaggrin panel; 1d and e).
In mouse skin carcinogenesis, reduction and eventual loss of endogenous keratin K1 expression is an excellent, consistent marker to assess malignant conversion and the progression stage achieved. 14, 26, 27 Hence, HK1.ras/fos-D5PTEN flx papillomas possessed high K1 expression that dominates K14 counterstaining and a predominately green colour in double-label micrographs ( Figure 3 Pre-malignant keratinocyte proliferation exhibits little increase following malignant conversion BrdU-labelling data (Figure 4 ) indicated that the inhibition of early-stage malignant progression maybe due to cell cycle inhibition. Typically, acquisition of each additional mutation gives a sequential increase in keratinocyte proliferation rate (Figure 4 Despite their high mitotic index (51.7 ± 5.2), HK1.ras/ fos-D5PTEN flx papilloma conversion was delayed compared with TPA-promoted bi-genic HK1.ras-D5PTEN flx mice, and this may be due in part to the diversion of excessive keratinocyte proliferation into cyst formation (57.7 ± 4.3), instead of the increased differentiation that abruptly reduced proliferation rates (34.2±8.4) in HK1.fos-D5PTEN flx KA aetiology. 27 However following conversion, neither tri-genic K1-positive wdSCCs (60.2 ± 8.3) nor later K1-negative SCCs ( 88.8 ± 4.6) exhibited the massive increase in labelled cells displayed by TPA-promoted (121.5±15.5) or rare spontaneous bi-genic HK1.ras-D5PTEN
flx SCCs (120.1 ± 9.4). Thus, the limited progression observed in K1-positive, tri-genic wdSCCs may be due to a degree of retained cell cycle regulation creating a hiatus in proliferation following malignant conversion and thereby stalling malignant progression. flx keratoacanthoma exhibits premature differentiation giving rise to basal layer micro-cysts (bars: e and f, B200 mm; j and k, B150 mm; g, 100 mm; h and i, 50 mm).
Inhibited carcinogenesis in ras
Ha /fos/PTEN flx mice FH Macdonald et al p53 and p21 in pdSCCs, which exhibited high cyclin D1/E2 and PCNA expression (Nb: in HK1.fos-D5PTEN flx KAs elevated p53/p21 expression and elevated cyclin expression proved to be in mutually exclusive histotypes 27 ). Immunohistochemical analysis of p53 and p21 expression ( Figure 5 and Figure 6 ; Supplementary Figure S2-S6) support these western data. All HK1.ras/fos-D5PTEN flx hyperplasia, cysts and papillomas expressed high p53 levels, with strong punctate expression in the nuclei of basal layer keratinocytes ( Figure 5 ; Supplementary Figures S2-S4) . Furthermore, following an initial downregulation in hyperplasia due to PTEN loss, bi-genic HK1.ras-D5PTEN flx papillomas re-expressed elevated p53 levels (and subsequent p21 also; Supplementary Figure S2 and S6) to account for their low spontaneous conversion rates. 26 In tri-genic papillomas, as expected, In contrast, while p53 expression was lost during papilloma conversion, p21 expression persisted in wdSCCs ( Figure 6 ). Analysis of hyperplasia/cysts found that initial p21 expression trailed that of p53 and this p53-associated p21 expression initially appeared in proliferative basal layers, diminished in supra-basal spinus keratinocytes to return in granular layers ( Figure 6 ; upper panels; Supplementary Figure S2 and S5). [18] [19] [20] In papillomas, p21 expression became uniform and following p53 loss, persisted during papilloma conversion to wdSCC ( Figure 6 : conversion panels). This p53-independent expression result suggests that p21 may be a significant antagonist to early-stage malignant progression (below), until its expression becomes interdicted/downregulated. This idea was supported by analysis of (K1/p53-negative) SCC nests where punctate, p21 expression persisted in basal layer nuclei ( Figure 6 : SCC progression panels; Supplementary Figure S4 ) until, in a similar fashion to p53 loss, p21 expression became cytoplasmic/peri-nuclear and disappeared (Supplementary Figure S5) . In comparison, TPA-promoted HK1.ras-D5PTEN flx tumours had lost p21 expression in their (rapid) progression to pdSCC (Supplementary Figure S6) . 
Ha /fos/PTEN flx mice FH Macdonald et al Downregulation of cyclin E2 associates with persistent p21 expression, whereas cyclin D1 expression appears reduced and redistributed throughout wdSCC cells Given the lack of increased proliferation in early wdSCCs and the reduced PCNA/cyclin E2 but not cyclin D1 expression in westerns, cyclin expression was further investigated via immunofluorescence ( Figure 7) . Analysis of tri-genic hyperplasia, papilloma or cyst biopsies, together with TPA-promoted papillomas and pdSCCs, showed elevated cyclin levels consistent with western analysis (Figure 7 , cyclin E2 panels: a-d; cyclin D1 panels: a and b). Routinely tri-genic hyperplasia/papilloma micrographs displayed clear, punctate nuclear expression of both cyclins, indicative of a high keratinocyte proliferation rate that was restricted to proliferative basal layers (Figure 7 , cyclin E2 panels: a and b; cyclin D1 panel: a). TPA-promoted carcinomas also showed increased numbers of cyclin-expressing cells that were no longer confined to basal layers ( Figure 7 , cyclin E2 panels: c and d; cyclin D1 result identical [not shown]). Hence, in pre-malignant phenotypes, hyper-proliferation and elevated cyclin expression was counterbalanced by p53/p21 to result in a relatively normal differentiation profile. As tri-genic papillomas began their conversion, the dynamics of differentiation shifted and increased cyclin expression appeared together with clusters of BrdU-labelled/p53-negative basal layer keratinocytes ( However, in HK1.ras/fos-D5PTEN flx wdSCCs, initial analysis gave inconsistent or inconclusive results, but once experimental parameters were re-defined, it became clear that cyclin E2 expression flx pdSCCs possess a significant increase in BrdU labelling (121.5±15.5). Lower panels: Western analysis of p53, p21, cyclins D1/E2 and PCNA expression in HK1.ras/fos-D5PTEN flx carcinogenesis. Biopsies comprised dorsal skin hyperplasia (H), papilloma (P) and carcinoma (C) or mixed tumour ( P / C ) collectively taken from an individual HK1.ras/fos-D5PTEN flx mouse and compared to bi-genic controls, normal back (B) or ear (E) skin. All HK1.ras/fos-D5PTEN flx hyperplasia and most papillomas expressed high p53 levels unless converting ( P / C ) or wdSCC. Bi-genic control hyperplasias lacked p53 until re-expression appeared in overt tumours (H versus P; H versus KA) and TPA-promoted bi-genic HK1.ras-D5PTEN flx possessed reduced or lacked p53 expression which was absent in all carcinomas. Elevated p21 expression in hyperplasia/papillomas persisted in wdSCC histotypes but became lost in more aggressive SCCs and TPA-promoted HK1.ras-D5PTEN flx pdSCCs. Cyclin D1 expression was elevated in all histotypes, although some carcinomas exhibited reduced levels unlike high Cyclin D1 expression in TPA-promoted HK1.ras-D5PTEN flx carcinomas. Most wdSCCs expressed reduced cyclin E2 and PCNA which paralleled persistent p21expression and became elevated in p21-negaitve TPA-promoted HK1.ras-D5PTEN flx carcinomas. In KAs, elevated p53/p21 and cyclins were expressed in mutually exclusive histotypes. b-actin expression served as a loading control.
Ha /fos/PTEN flx mice FH Macdonald et al was reduced in wdSCCs ( Figure 7 , cyclin E2 panels: e-h) and this was paralleled by reduced cyclin D1 expression also ( Figure 7 , cyclin D1 panels: c-f), which contrasted with western data (above). For cyclin E2, a composite section through a typical ear biopsy ( Figure 7 , cyclin E2 panel: e) shows that easily detectable cyclin E2-positive keratinocytes in hyperplastic basal layers became reduced or undetectable on conversion to a wdSCC histotype (cyclin E2 staining is deliberately overexposed in the right hand micrograph). At higher magnification (Figure 7 , cyclin E2 panels: f-h), typical trigenic wdSCCs possessed low, almost undetectable cyclin E2, and in serial sections reduced/negative cyclin E2 expression paralleled elevated p21 expression (Figure 6 ), until p21 expression was lost (for example, SCC 'nests' Figure 6 ) and nuclear cyclin E2 expression reappeared ( Figure 7 , cyclin E2 panel: i).
At first sight, cyclin D1 presented a similar storey, as high nuclear basal expression paralleled that of cyclin E2 in benign biopsies ( Figure 7 , cyclin D1 panels: a and b) and TPA-promoted carcinomas (not shown). However, on conversion, typical (K1-positive/p53-negative/p21-positive) wdSCC histotypes exhibited reduced cyclin D1 (Figure 7 , cyclin D1 panels: c-f) in apparent contrast to western data. Closer examination found that many wdSCC keratinocytes possessed low-level, punctate cyclin D1 expression ( Figure 7 , cyclin D1 panels: e and f) randomly redistributed throughout wdSCCs and certain cells possessed strong, peri-nuclear cyclin D1 (Figure 7 , cyclin D1 panels: c-g). Indeed, despite the dangers of over-interpretation, there was a suspicion that this punctate, cyclin D1 profile appeared within the nucleus, possibly at the nuclear membrane ( Figure 7 , cyclin D1 panels: c-g). This cyclin D1 expression profile helps accommodate the observation of persistent expression in westerns despite elevated p21 or reduced PCNA and cyclin E2 levels. Nonetheless, on progression to more aggressive (K1-negaitve) SCCs, cyclin D1 expression returned to increased levels in nuclei of proliferating cells, as recorded for cyclin E2.
DISCUSSION
These HK1.ras/fos-D5PTEN flx data demonstrate direct co-operation between inducible PTEN loss and epidermal expression of activated ras Ha and fos oncogenes. Their synergism resulted in a rapid papillomatogenesis, yet despite three potent oncogenic insults when compared with chemical carcinogenesis studies, 24, 25 malignant conversion was delayed, non-uniform/patchy, and early-stage malignant progression was inhibited. PTEN loss Figure 5 . p53 expression in pre-neoplastic, pre-malignant and malignant HK1.ras/fos-D5PTEN flx histotypes. Top panels: low magnification composites of hyperplasia and proliferative cysts show strong p53 expression in all epidermal compartments. Early HK1.ras/fos-D5PTEN papillomas exhibit strong p53 expression with increasing areas of reduced expression (boxed). Lower panels: as papillomas progress, elevated p53 expression in basal layer nuclei becomes reduced and strands of p53-negative keratinocytes appear at sites of disordered basal layer architecture. p53 expression is lost on progression to K1-positive wdSCCs or K1-negative SCC nests (bars: top panel B100, 200 mm; papilloma: 50, 25 mm; wdSCC: B200, 50, 25 mm).
Inhibited carcinogenesis in ras
Ha /fos/PTEN flx mice FH Macdonald et al induced malignant conversion of otherwise stable, autonomous HK1.ras/fos papillomas, 14 a result that might be anticipated given the cooperation observed previously between MAPK deregulation and PTEN loss. 6, 10, [26] [27] [28] [29] [30] Hence, the greater implication of these data may lie in identification of specific epidermal responses deployed to counter these mutations; employing a multi-stage model with the viability/phenotype stability that enables investigation of the nuances that drive malignant conversion/progression. 3, 7, 31 Furthermore, these data highlight the importance of the context to the final tumour outcome, as progression mechanism(s) depended upon the cellular/tissue responses [4] [5] [6] [24] [25] [26] [27] that strived to cope with the re-wired oncogenic circuitry in specific cell populations. 13 In this model, temporal acquisition of mutant PTEN depends on topical RU486 to inactivate phospholipase function(s) (but not auto-phosphorylation 30, 32 ) in follicular and interfollicular keratinocytes, including stem cells. 26, 27, 29 PTEN loss alone and resultant AKT/PI3Kinase deregulation 10 result in follicular and epidermal hyperplasia/hyperkeratosis. [24] [25] [26] [27] In RU486-treated HK1.ras/ fos-D5PTEN flx epidermis, these interfollicular D5PTEN-mutated keratinocytes are waylaid at the transit-amplifying stage by ras Ha /fos activation expressed from a modified keratin 1-based vector.
14 In theory, therefore, HK1.ras/fos-D5PTEN flx synergism possess the major elements of two-stage DMBA/TPA carcinogenesis, that is, ras Ha -mediated initiation and c-fos/AP1-mediated promotion, 15 yet HK1.ras/fos-D5PTEN flx mice achieved only a fraction of DMBA/TPA-mediated PTEN null tumourigenesis 24, 25 due to high levels of p53 trailed by p21 expression; moreover, early-stage malignant progression following p53 loss was inhibited by persistent, p53-independent p21 expression.
17,22
Figure 6. p21 expression in pre-neoplastic, pre-malignant and malignant HK1.ras/fos-D5PTEN flx histotypes. Top panels: elevated p21 expression in hyperplasia and cysts show a delayed, bi-phasic expression profile, that is less expression in spinus layers (see Supplementary Figure S4 ). p21 expression in larger cysts and papillomas became elevated and uniform. Lower panels: as papillomas converted, elevated p21 expression persisted and in instances of early stage invasion appeared to increase. Following conversion and progression p21 expression persisted in wdSCCs (top) and invasive (K1-postive/p53 negative) wdSCC nests (middle), but in (K1-negative) aggressive SCC (bottom), p21 expression became reduced, cytoplasmic/peri-nuclear and faded (bars: top panels: B200, 100, 50 mm; papilloma: 100, 50, 25 mm; wdSCC: B200, 100, 50, 25 mm).
Inhibited carcinogenesis in ras
Ha /fos/PTEN flx mice FH Macdonald et al Such compensatory p53/p21 expression (amongst others 5, 33, 34 ), maybe a common feature deployed to combat deregulated MAPK/PTEN null synergism, [4] [5] [6] 19, 21, 30 and their potency was demonstrated in TPA-promoted, bi-genic HK1.ras-D5PTEN flx cohorts, where loss of p53/p21 expression during papillomatogenesis (Supplementary Figure S6 26 ) resulted in a rapid, 100% conversion rate and swift progression to pdSCCs. 24, 25 In contrast, spontaneous malignant conversion was rare in HK1.ras-D5PTEN flx cohorts due to persistent p53 and p21 expression, which countered ras Ha co-operation with D5PTEN-mediated AKT activation 26 producing stable papillomas, similar to HK1.ras/fos controls. 14 Directly demonstrating the importance of context to the final tumour outcome, and highlighting that epidermal responses flx pdSCCs exhibit strong basal and supra-basal cyclin E2. (e) Papilloma conversion to wdSCC shows papilloma cyclin E2 expression (left) fades on traversing to wdSCC (right), despite deliberate FITC overexposure. (f-h) wdSCCs were low or negative for cyclin E2, until (i) nuclear cyclin E2 expression returned on progression to K1-negative SCC. Lower panel: Cyclin D1 expression: (a) HK1.ras/fos-D5PTEN flx hyperplasia displays elevated nuclear cyclin D1 expression, also prominent in (b) papilloma basal layers with p53-negative/ragged K1 expression. (c) HK1.ras/fos-D5PTEN flx wdSCCs exhibit reduced cyclin D1 in basal layer nuclei, which (d) became more diffuse and (e) expressed in most wdSCC keratinocytes in a punctate, low-level fashion (f and g). In wdSCCs, this diffuse punctate cyclin D1 expression often appeared peri-nuclear or possibly at the nuclear membrane (bars: upper panel: a, b and d 100 mm; e and f 50 mm; c and g-i: 25 mm. Lower panel: a 100 mm; b-e 50 mm; f and g: 25 mm).
Ha /fos/PTEN flx mice FH Macdonald et al can exploit terminal differentiation to inhibit progression, compensatory p53/p21 expression in HK1.fos-D5PTEN flx cohorts produced benign keratoacanthomas not carcinomas. 27 In this earlier, bi-genic context, threshold levels of GSK3b inactivation 35, 36 induced p53/p21 to downregulate p-AKT [4] [5] [6] 10, 28, 30 and committed proliferative benign keratinocytes into a fos/p21-associated differentiation programme, 9, 17, 20, 37 resulting in the classic hallmark keratosis of KAs. 27 Here, proliferative HK1.fos-D5PTEN flx keratinocytes were continually diverted into (atypical) differentiation, providing an elegant mechanism that removed potentially malignant cells. Indeed, this differentiation option maybe preferable to stratified epithelia as opposed to widespread apoptosis, which would be disadvantageous to barrier functions. Hence, elevated p21 appears in PTEN null bladder hyperplasia unlike glandular epithelia of early prostate carcinogenesis. 21, 35 In pre-malignant HK1.ras/fos-D5PTEN flx histotypes, additional ras Ha activation negated an effective differentiation response as, despite p53/p21 appearing in the earliest HK1.ras/fos-D5PTEN flx hyperplasias, a 50% increase in mitotic index was recorded that paralleled increases in PCNA and cyclin D1/E2 expression. In both hyperplasia and cysts, p53 expression preceded that of p21, suggesting that p21 expression was induced by p53, as observed in bi-genic HK1.fos-D5PTEN flx KAs; 27 further, this subsequent p21 expression was bi-phasic, appearing in basal layers and again in granular cells, consistent with key alternate roles in keratinocyte differentiation. 20 Hence, alarm signals to trigger p53 and p53-dependent p21 expression, such as a GSK3b inactivation, 27, 35, 36 responded to ras Ha /fos/PTEN-induced hyperproliferation far earlier than in bi-genic cohorts. Indeed, p53/p21 expression in bi-genic hyperplasia was undetectable 26, 27 until the overt tumour stage (Figure 4; Supplementary Figure S2) , a result more consistent with studies where PTEN loss induced p53 loss, 4, 10, 30 whereas chemical promotion quickly eliminated p53/p21 and inactivated any compensatory re-appearance in papillomas (Supplementary Figure S6) , [24] [25] [26] presumably due to additional genetic/epigenetic insults.
Despite their failure to quell hyper-proliferation, immediate p53/p21 expression in HK1.ras/fos-D5PTEN flx cohorts altered the proliferation/differentiation dynamic to restore a relatively ordered keratinocyte differentiation profile and this potentially contributed to the striking appearance of multiple, proliferative cysts, an epidermal response phenotype previously observed in studies to assess b-catenin signalling in follicular differentiation. 38 As HK1.ras/fos transgenes are not expressed in follicles 14 and HK1.ras/fos-D5PTEN flx cysts expressed interfollicular differentiation markers, it suggests that excess interfollicular proliferation was diverted into 'dead end' cysts that lacked even benign tumour potential due to persistent p53/p21 expression. This may represent another example of coping strategies available to epidermis/stratified epithelia, 38, 39 and progression/inhibition mechanisms involving GSK3b-mediated failures to integrate b-catenin/Wnt signalling are under investigation. 40 At this juncture of elevated p53/p21 expression there appeared little in the way of overt progression: differentiation markers (keratin K1/loricrin) were expressed in an ordered, fashion; even filaggrin expression rallied somewhat in cysts and papillomas, and BrdU-labelling, albeit extensive, remained confined to proliferative basal layers. However, such efficacy 34 reduces with increasing transformation/additional mutations, 3, 7 thus by 4 months HK1.ras/fos-D5PTEN flx papillomas converted to malignancy. The progression scenario began (B10-12 weeks) with subtle changes to the status quo of papilloma basal layer architecture, detected by delayed/ragged K1 expression, suggesting that the ordered transition of keratinocytes into their differentiation programme was altered. HK1.ras/fos-D5PTEN flx papillomas also possessed intercellular gaps, giving a loose, spongiosis-like histotype suggesting failures/changes in cell-cell adhesion that maintain epidermal integrity. Given the membrane-scaffolding functions previously attributed to PTEN in adhesion, 40 these altered cell-cell/cell-matrix interactions would be consistent with a role for PTEN loss in the predisposition of (otherwise stable) HK1.fos/ras papillomas to malignant conversion. 14 Among the first causal indications of papilloma conversion was the (well characterized 16 ) loss of p53 expression. Initially detected in strands of basal layer nuclei at sites of ragged K1 expression, this gave rise to clusters of BrdU-labelled, cyclin D1/E2-expressing keratinocytes. 41, 42 Logically, changes in keratinocyte proliferation and altered differentiation state would be amongst the first indications of malignant potential, 3 while appearance of 'strands' of p53-negative keratinocytes may indicate an origin from initiated, interfollicular stem cells, consistent with recent studies defining the cancer stem cell niche in classic multi-stage mouse skin carcinogenesis. 43 However, proliferation per se does not necessarily equate to progression, for example, CDK2 activation in transgenic epidermis induces keratinocyte proliferation but not carcinogenesis. 44 One feature of p53 loss not associated with archetypal failures in cell cycle control is the resultant chromosomal instability engendered by a lack of DNA repair, 12 which was a major feature driving malignant progression in twostage chemical carcinogenesis employing gain-of-function p53 transgenic mice. 45 Recent studies demonstrate that chromosomal instability following loss of p53 function, as opposed to gain-offunction mutants, 45 became causal at the later stages that drive malignant progression. 46 Hence, during the early stages of malignant progression there may be a trade-off between proliferation/metabolism and genomic instability. 3, 7, 12, 31 Thus, it is noteworthy that in addition to p21-mediated cyclin regulation (below), p21-mediated tumour suppression is also associated with maintaining chromosomal stability. 22 Therefore, following p53 loss, one facet of persistent, p53-independent, p21 expression may highlight this trade-off: on one hand limiting proliferation via canonical cyclin regulation (below), 11, 41, 42 while also limiting earlystage malignant progression via indirect effects on chromosomal stability. 22 If so, based on HK1.ras/fos-D5PTEN flx data, elements of p21-mediated cyclin D1 regulation maybe involved.
Western analysis of cyclin D1 expression in p53-negative wdSCCs showed levels inconsistent with elevated p21, decreased PCNA and a flatlined mitotic index, whereas immunofluorescence demonstrated that elevated cyclin D1 expression observed in hyperplastic/papilloma basal layer nuclei became diffuse following conversion to (p53-negative, p21/K1-positive) wdSCCs. Furthermore, detectable low-level cyclin D1 expression was no longer restricted to basal layers, becoming randomly redistributed throughout the tumour, while occasional wdSCC keratinocytes exhibited a strong, punctate peri-nuclear/nuclear membrane expression profile. This in situ expression analysis explained the western anomaly of elevated cyclin D1 and p21/PCNA/mitotic index, but of greater significance maybe that this redistribution also reflects the novel role for cyclin D1 recently identified in DNA repair. 47 Given the combined loss of p53 12 and the gate-keeping/ DNA repair functions also attributed to PTEN, 48 the potential lack of DNA repair abilities would be a major facet to drive progression in HK1.ras/fos-D5PTEN flx wdSCCs. Hence, a putative feedback loop, mediated by p21/others may divert cyclin D1 into a DNA-repair mode 47 to aid in maintaining chromosomal integrity, 12, 22, 46 whilst diversion away from cell-cycle roles would account for flatlined wdSCC keratinocyte proliferation. Thus, it is noteworthy that p21 acts as an assembly factor for cyclin D1-CDK4 complexes, separate from the well-characterized inhibitory kinase activity in regulation of cyclin E (below), 11, 44, 49 and links p21 to cyclin D1 in this putative DNA repair mechanism. Indeed, evidence exists that p21-mediated reduction of cyclin E family members may contribute to this putative mechanism, given their roles in the inhibition of DNA repair. 50, 51 In respect to p21, its exact roles in carcinogenesis still remain unclear. 11, [17] [18] [19] [20] Employing a tagged p21 transgene, elevated flx data that demonstrate persistent p21 was integral to maintenance of wdSCC histotypes. A later causality would also be consistent with roles in chromosomal stability outlined above following p53 loss. 22 Whether this model would mimic studies finding earlier roles for p21 loss 18, 19 await p21 knockout, and such experiments are ongoing. In limiting malignant progression to wdSCC, a more orthodox role for p53-independent, persistent p21 expression centres on inhibition (redistribution?) of cyclin D1 and E2 expression to limit proliferation. Initially, both cyclins were highly expressed alongside p53/p21, but became oddly difficult to detect following p53 loss and conversion. It may be that p53 loss creates an eddy in efficient proliferation and feedback systems 'sense' loss of the guardian function/DNA repair 12 and attempt to inhibit cell cycle via persistent p21 (and p16 33 ) expression. Thus, to inhibit CDK2-mediated cell proliferation, elevated p21 expression forms inactive complexes with cyclin E family members. 41, 42 Furthermore, as outlined above, p21 regulation of cyclin/CDK complexes is under exquisite control, such that a low level of p21 exerts a positive proliferation role as an assembly factor for cyclin D1-CDK4 complexes. 44, 49 These dual aspects of p21 function may underlie contrasting observations of early and late roles in carcinogenesis or the inhibited epidermal differentiation versus proliferation observed in p21 knockouts, 17, 20 which echoes bi-phasic, p53-associated p21 expression profiles observed in HK1.ras/fos-D5PTEN flx hyperplasia. Collectively, HK1.ras/fos-D5PTEN flx data establish a carcinogenesis model possessing sufficient viability to study multiple genetic interactions and analyse the specific response mechanisms that inhibit malignant conversion and limit early-stage progression. Alongside its allies, this study shows that a p53-independent, p21 expression response appeared quite potent, able to limit progression to wdSCC for reasonable time periods, until reduction and loss of p21 gave more aggressive SCCs in a mechanism associated with increasing p-AKT activities 10,24-27,52 (Yao et al.; manuscript in preparation). Ideally, investigation of the interplay between these common mutations to determine how compensatory mechanisms become circumvented will aid in developing the therapies geared to reactivating p53/p21 function or that target ras/MAPK/fos and PTEN/AKT/mTOR signalling pathways.
METHODS
Breeding genotypes and tumour induction
Breeding strategies maintained HK1.ras/fos and RU486-inducible K14.creP regulator 14, 26, 27, 29 as heterozygous transgenes in mice homozygous for lox-P-flanked-PTEN exon 5 alleles (D5PTEN; 30 HK1.ras/fos-D5PTEN flx ). Progeny were genotyped by PCR as described. 26, 27 PTEN function was inactivated in epidermis following topical treatment of 5-6-week old adult skin with 2 mg RU486 (Sigma, Gillingham, UK) dissolved in 20 ul ethanol, weekly for 3 weeks, with controls receiving ethanol alone (see Supplementary Figure S1 ). 29 SCCs were raised in RU486-treated bi-genic HK1.ras-D5PTEN flx mice via topical treatment with 2.5 mg of TPA/50 ml acetone per week (50 ml of 1.6 Â 10 À 4 M TPA) for 3 weeks. All experiments adhered to UK Experimental Regulations (Licence: 60/4318 to DAG).
